Buflomedil
Names | |
---|---|
IUPAC name
4-(pyrrolidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
ECHA InfoCard | Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). |
PubChem CID
|
|
| |
| |
Properties | |
C17H25NO4 | |
Molar mass | 307.38 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
WikiDoc Resources for Buflomedil |
Articles |
---|
Most recent articles on Buflomedil |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Buflomedil at Clinical Trials.gov Clinical Trials on Buflomedil at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Buflomedil
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Buflomedil Discussion groups on Buflomedil Patient Handouts on Buflomedil Directions to Hospitals Treating Buflomedil Risk calculators and risk factors for Buflomedil
|
Healthcare Provider Resources |
Causes & Risk Factors for Buflomedil |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Buflomedil is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States. Currently available as trade name tablet Loftyl
Toxicity
This drug might be suspended from marketing in the European Union, because of concerns about severe neurological and cardiac toxicity.[1][2] In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options".
Various adverse effects have been reported to the FDA.[3]